News for Healthier Living

Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic Leukemia

Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH, Assistant Professor of Oncology in Roswell Park's departments of Medicine and Cancer Genetics & Genomics, is first author of the study, which he will present during an oral abstract session today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.

December 7, 2024


December 21 2024

December 20 2024

December 19 2024

December 18 2024

December 17 2024

December 16 2024

December 15 2024

December 14 2024

December 13 2024

December 12 2024

December 11 2024

December 10 2024

December 9 2024

December 8 2024

December 7 2024